{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:27:18Z","timestamp":1788449238554,"version":"build-2803163510"},"reference-count":58,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.euf.2018.07.032","type":"journal-article","created":{"date-parts":[[2018,8,8]],"date-time":"2018-08-08T18:33:18Z","timestamp":1533753198000},"page":"494-502","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Predicting Response to Intravesical Therapy in Non\u2013muscle-invasive Bladder Cancer"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0916-5787","authenticated-orcid":false,"given":"Mahmoud","family":"Alameddine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Kineish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Ritch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2018.07.032_bib0005","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.07.032_bib0010","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.eururo.2017.10.003","article-title":"Predicting response to intravesical bacillus Calmette-Guerin immunotherapy: are we there yet? A systematic review","volume":"73","author":"Kamat","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.07.032_bib0015","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.juro.2013.04.031","article-title":"SWOG S0353: phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guerin","volume":"190","author":"Skinner","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.07.032_bib0020","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.urolonc.2012.04.010","article-title":"Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guerin","volume":"31","author":"Dinney","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2018.07.032_bib0025","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.juro.2017.04.077","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in a United States population","volume":"198","author":"Ravvaz","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.07.032_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2016.10.021","article-title":"Preoperative anemia is associated with disease recurrence and progression in patients with non-muscle-invasive bladder cancer","volume":"35","author":"Soria","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2018.07.032_bib0035","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1\u20133 years of maintenance bacillus Calmette-Guerin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.07.032_bib0040","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.eururo.2016.02.031","article-title":"Papillary recurrence of bladder cancer at first evaluation after induction Bacillus Calmette-Guerin therapy: implication for clinical trial design","volume":"70","author":"Mmeje","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.07.032_bib0045","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2014.06.040","article-title":"Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with bacillus Calmette-Guerin: results of a retrospective multicenter study of 2451 patients","volume":"67","author":"Gontero","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.07.032_bib0050","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00345-015-1598-0","article-title":"Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation","volume":"34","author":"Lammers","year":"2016","journal-title":"World J Urol"},{"key":"10.1016\/j.euf.2018.07.032_bib0055","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2011.10.029","article-title":"Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guerin","volume":"62","author":"Palou","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.07.032_bib0060","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.juro.2010.08.083","article-title":"Usefulness of the Spanish Urological Club for Oncological Treatment scoring model to predict nonmuscle invasive bladder cancer recurrence in patients treated with intravesical bacillus Calmette-Guerin plus interferon-alpha","volume":"185","author":"Rosevear","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.07.032_bib0065","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.07.032_bib0070","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.07.032_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2016.05.014","article-title":"Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer","volume":"34","author":"Passoni","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2018.07.032_bib0080","doi-asserted-by":"crossref","first-page":"e755","DOI":"10.1016\/j.clgc.2017.03.007","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in primary non-muscle-invasive bladder cancer","volume":"15","author":"D\u2019Andrea","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euf.2018.07.032_bib0085","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.urpr.2017.02.012","article-title":"Association between metabolic syndrome and recurrence of nonmuscle invasive bladder cancer following bacillus Calmette-Guerin treatment","volume":"5","author":"Lenis","year":"2018","journal-title":"Urol Pract"},{"key":"10.1016\/j.euf.2018.07.032_bib0090","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ucl.2015.08.005","article-title":"Current status of urinary biomarkers for detection and surveillance of bladder cancer","volume":"43","author":"Mbeutcha","year":"2016","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.euf.2018.07.032_bib0095","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4103\/0974-7796.95550","article-title":"The influence of urine cytology on our practice","volume":"4","author":"Alameddine","year":"2012","journal-title":"Urol Ann"},{"key":"10.1016\/j.euf.2018.07.032_bib0100","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/S0022-5347(05)67104-2","article-title":"A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma","volume":"164","author":"Halling","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.07.032_bib0105","doi-asserted-by":"crossref","first-page":"922","DOI":"10.7326\/M15-0997","article-title":"Urinary biomarkers for diagnosis of bladder cancer: a systematic review and meta-analysis","volume":"163","author":"Chou","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.euf.2018.07.032_bib0110","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/S0022-5347(05)64270-X","article-title":"Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer","volume":"168","author":"Sarosdy","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.07.032_bib0115","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1016\/j.juro.2008.01.105","article-title":"Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder","volume":"179","author":"Lotan","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.07.032_bib0120","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/01.ju.0000149825.83180.a4","article-title":"Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization","volume":"173","author":"Kipp","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.07.032_bib0125","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.juro.2011.10.144","article-title":"Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guerin therapy for bladder cancer: results of a prospective trial","volume":"187","author":"Kamat","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.07.032_bib0130","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/bju.13186","article-title":"Novel fluorescence in situ hybridization-based definition of bacille Calmette-Guerin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies","volume":"117","author":"Kamat","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2018.07.032_bib0135","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.eururo.2008.09.062","article-title":"Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guerin","volume":"56","author":"Palou","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.07.032_bib0140","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.eururo.2012.05.033","article-title":"Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer","volume":"65","author":"Bertz","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.07.032_bib0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2017.03.010","article-title":"Validation of the ezrin, CK20, and Ki-67 as potential predictive markers for BCG instillation therapy of non-muscle-invasive bladder cancer","volume":"35","author":"Malmstrom","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2018.07.032_bib0150","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1016\/j.juro.2011.06.051","article-title":"Predictive value of microtubule associated proteins tau and stathmin in patients with nonmuscle invasive bladder cancer receiving adjuvant intravesical taxane therapy","volume":"186","author":"Wosnitzer","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.07.032_bib0155","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.eururo.2012.05.050","article-title":"Polyamine-modulated factor-1 methylation predicts bacillus Calmette-Guerin response in patients with high-grade non-muscle-invasive bladder carcinoma","volume":"63","author":"Alvarez-Mugica","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.07.032_bib0160","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.urolonc.2011.06.004","article-title":"Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?","volume":"31","author":"Park","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2018.07.032_bib0165","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1038\/bjc.2013.571","article-title":"Response of high-risk of recurrence\/progression bladder tumours expressing sialyl-Tn and sialyl-6-T to BCG immunotherapy","volume":"109","author":"Lima","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euf.2018.07.032_bib0170","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/ng1061","article-title":"Identifying distinct classes of bladder carcinoma using microarrays","volume":"33","author":"Dyrskjot","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.euf.2018.07.032_bib0175","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1158\/0008-5472.CAN-03-3620","article-title":"Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification","volume":"64","author":"Dyrskjot","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.euf.2018.07.032_bib0180","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1158\/1078-0432.CCR-04-2095","article-title":"A molecular signature in superficial bladder carcinoma predicts clinical outcome","volume":"11","author":"Dyrskjot","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euf.2018.07.032_bib0185","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.eururo.2017.05.040","article-title":"Prognostic impact of a 12-gene progression score in non-muscle-invasive bladder cancer: a prospective multicentre validation study","volume":"72","author":"Dyrskjot","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.07.032_bib0190","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/bju.12844","article-title":"The role of functional polymorphisms in immune response genes as biomarkers of bacille Calmette-Guerin (BCG) immunotherapy outcome in bladder cancer: establishment of a predictive profile in a Southern Europe population","volume":"116","author":"Lima","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2018.07.032_bib0195","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","article-title":"Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets","volume":"72","author":"Pietzak","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.07.032_bib0200","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/cncy.21847","article-title":"Next-generation sequencing of urine specimens: a novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guerin","volume":"125","author":"Scott","year":"2017","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.euf.2018.07.032_bib0205","doi-asserted-by":"crossref","DOI":"10.1038\/srep14000","article-title":"GSTP1 and GSTO1 single nucleotide polymorphisms and the response of bladder cancer patients to intravesical chemotherapy","volume":"5","author":"Deng","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.euf.2018.07.032_bib0210","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrurol.2015.58","article-title":"Expert consensus document: consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer","volume":"12","author":"Kamat","year":"2015","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euf.2018.07.032_bib0215","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003586","article-title":"Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer","volume":"4","author":"Biot","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.euf.2018.07.032_bib0220","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.eururo.2015.06.023","article-title":"Cytokine Panel for Response to Intravesical Therapy (CyPRIT): nomogram of changes in urinary cytokine levels predicts patient response to Bacillus Calmette-Guerin","volume":"69","author":"Kamat","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.07.032_bib0225","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0006-2952(01)00831-0","article-title":"The signalling pathway for BCG-induced interleukin-6 production in human bladder cancer cells","volume":"63","author":"Zhang","year":"2002","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.euf.2018.07.032_bib0230","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1365-2249.2010.04105.x","article-title":"Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guerin (BCG)-induced macrophage cytotoxicity against bladder cancer cells","volume":"160","author":"Luo","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.euf.2018.07.032_bib0235","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3892\/etm.2012.634","article-title":"Prediction of response to bacillus Calmette-Guerin treatment in non-muscle invasive bladder cancer patients through interleukin-6 and interleukin-10 ratio","volume":"4","author":"Cai","year":"2012","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.euf.2018.07.032_bib0240","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1038\/sj.bjc.6601474","article-title":"Polarisation of a T-helper cell immune response by activation of dendritic cells with CpG-containing oligonucleotides: a potential therapeutic regime for bladder cancer immunotherapy","volume":"89","author":"Atkins","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euf.2018.07.032_bib0245","doi-asserted-by":"crossref","first-page":"39916","DOI":"10.18632\/oncotarget.9537","article-title":"Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical bacillus Calmette-Guerin therapy in bladder cancer","volume":"7","author":"Pichler","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.euf.2018.07.032_bib0250","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00262-016-1945-z","article-title":"Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer","volume":"66","author":"Pichler","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.euf.2018.07.032_bib0255","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1172\/JCI89717","article-title":"ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence","volume":"127","author":"Chevalier","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.euf.2018.07.032_bib0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2013.06.008","article-title":"Predicting response to bacillus Calmette-Guerin (BCG) in patients with carcinoma in situ of the bladder","volume":"32","author":"Nunez-Nateras","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2018.07.032_bib0265","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3109\/01913123.2012.728688","article-title":"Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy","volume":"37","author":"Ajili","year":"2013","journal-title":"Ultrastruct Pathol"},{"key":"10.1016\/j.euf.2018.07.032_bib0270","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.eururo.2015.02.032","article-title":"A systematic review of immunotherapy in urologic cancer: evolving roles for targeting of CTLA-4, PD-1\/PD-L1, and HLA-G","volume":"68","author":"Carosella","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.07.032_bib0275","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.euf.2018.07.032_bib0280","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.juro.2017.04.102","article-title":"Differential expression of PD-L1 in high grade T1 vs muscle invasive bladder carcinoma and its prognostic implications","volume":"198","author":"Wankowicz","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.07.032_bib0285","doi-asserted-by":"crossref","first-page":"75176","DOI":"10.18632\/oncotarget.12661","article-title":"Genomic characterization of high-risk non-muscle invasive","volume":"7","author":"Meeks","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.euf.2018.07.032_bib0290","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1245\/s10434-015-4431-5","article-title":"Genetic variations in glutathione pathway genes predict cancer recurrence in patients treated with transurethral resection and bacillus Calmette-Guerin instillation for non-muscle invasive bladder cancer","volume":"22","author":"Ke","year":"2015","journal-title":"Ann Surg Oncol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456918302165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456918302165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:47:22Z","timestamp":1762498042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456918302165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S2405456918302165"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2018.07.032","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting Response to Intravesical Therapy in Non\u2013muscle-invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2018.07.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}